Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia (RE-AFFIRM)

Tonix Pharmaceuticals

Status and phase: Terminated; Phase 3

Conditions: Myofascial Pain Syndromes; Fibromyalgia; Muscular Diseases; Neuromuscular Diseases; Musculoskeletal Diseases; Nervous System Diseases; Rheumatic Diseases

Treatments: Drug: TNX-102 SL Tablet, 2.8 mg; Drug: Placebo SL Tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT02829814

TNX-CY-F302

Details and patient eligibility

About

The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime after 12 weeks of treatment in patients with fibromyalgia.

The use of low-dose sublingual formulation of cyclobenzaprine (TNX-102 SL) dosed nightly for fibromyalgia is supported by the results of TNX-CY-F202 Phase 2b study -- the results provide strong evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial effects upon pain, sleep and other FM symptomatology.

Enrollment: 51 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Primary Fibromyalgia (2010 ACR criteria)
• Male or female 18-75 years old
• Patients currently receiving pharmacologic treatment for depression should have been clinically stable for at least 3 months prior to randomization, and on stable doses of antidepressants during this 3 month time frame.
• Willing and able to withdraw specific therapies (ask PI)
• If female, medically acceptable form of contraception or not of child bearing potential.
• Provide written informed consent to participate.
• Willing and able to comply with all protocol specified requirement.

Exclusion criteria

• Arthritis, lupus and other systemic auto-immune diseases
• Regional or persistent pain that could interfere with assessment of fibromyalgia pain
• Bipolar and psychotic disorders
• Increased risk of suicide
• Significant clinical (cardiac, systemic infection, systemic corticosteroid requirement, drug/alcohol abuse) or laboratory abnormalities.
• Inability to wash-out specific medications (ask PI)
• Known hypersensitivity to cyclobenzaprine
• Others: seizure disorders, severe/untreated sleep apnea, BMI>45

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

51 participants in 2 patient groups, including a placebo group

TNX-102 SL Tablet, 2.8 mg

Experimental group

Description:

1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks

Treatment:

Drug: TNX-102 SL Tablet, 2.8 mg

Placebo SL Tablet

Placebo Comparator group

Description:

1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks

Treatment:

Drug: Placebo SL Tablet